Cargando…

Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances

Eleven solid dispersions containing olanzapine, with carriers of different composition (Lutrol(®) F68, Lutrol(®) F127, Gelucire(®) 44/14), were prepared and examined by thermal (differential scanning calorimetry (DSC); thermomicroscopy (HSM)) and X-ray diffraction (XRD) analysis, both as fresh or ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavallari, Cristina, Fini, Adamo, Ceschel, Giancarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873680/
https://www.ncbi.nlm.nih.gov/pubmed/24300563
http://dx.doi.org/10.3390/pharmaceutics5040570
_version_ 1782297137701191680
author Cavallari, Cristina
Fini, Adamo
Ceschel, Giancarlo
author_facet Cavallari, Cristina
Fini, Adamo
Ceschel, Giancarlo
author_sort Cavallari, Cristina
collection PubMed
description Eleven solid dispersions containing olanzapine, with carriers of different composition (Lutrol(®) F68, Lutrol(®) F127, Gelucire(®) 44/14), were prepared and examined by thermal (differential scanning calorimetry (DSC); thermomicroscopy (HSM)) and X-ray diffraction (XRD) analysis, both as fresh or aged (one year) samples. Drug and carriers were preliminarily selected in order to avoid problems related to the aging of the formulation, according to the solubility parameters of carriers and drug. These parameters make it possible to predict the low solubility of olanzapine in the carriers (alone or in mixtures). Systems containing only Lutrol (also in the presence of Transcutol(®)) contain the drug in the form of particles of reduced size and in a crystalline form. Gelucire(®) 44/14 apparently increases the amount of olanzapine dissolved in the solid carrier, but this is presumed to be a metastable state, probably related to the heterogeneous nature of the carrier that delays crystallization of the drug. The high hydrophilicity of the carriers proves suitable to an accelerated and quick release of the drug regardless of aging. Differences in the release profiles between Lutrol- and Gelucire-containing systems were interpreted in terms of the formation of polymer micelles by the Lutrols when in aqueous solution.
format Online
Article
Text
id pubmed-3873680
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38736802014-01-06 Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances Cavallari, Cristina Fini, Adamo Ceschel, Giancarlo Pharmaceutics Article Eleven solid dispersions containing olanzapine, with carriers of different composition (Lutrol(®) F68, Lutrol(®) F127, Gelucire(®) 44/14), were prepared and examined by thermal (differential scanning calorimetry (DSC); thermomicroscopy (HSM)) and X-ray diffraction (XRD) analysis, both as fresh or aged (one year) samples. Drug and carriers were preliminarily selected in order to avoid problems related to the aging of the formulation, according to the solubility parameters of carriers and drug. These parameters make it possible to predict the low solubility of olanzapine in the carriers (alone or in mixtures). Systems containing only Lutrol (also in the presence of Transcutol(®)) contain the drug in the form of particles of reduced size and in a crystalline form. Gelucire(®) 44/14 apparently increases the amount of olanzapine dissolved in the solid carrier, but this is presumed to be a metastable state, probably related to the heterogeneous nature of the carrier that delays crystallization of the drug. The high hydrophilicity of the carriers proves suitable to an accelerated and quick release of the drug regardless of aging. Differences in the release profiles between Lutrol- and Gelucire-containing systems were interpreted in terms of the formation of polymer micelles by the Lutrols when in aqueous solution. MDPI 2013-10-25 /pmc/articles/PMC3873680/ /pubmed/24300563 http://dx.doi.org/10.3390/pharmaceutics5040570 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Cavallari, Cristina
Fini, Adamo
Ceschel, Giancarlo
Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances
title Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances
title_full Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances
title_fullStr Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances
title_full_unstemmed Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances
title_short Design of Olanzapine/Lutrol Solid Dispersions of Improved Stability and Performances
title_sort design of olanzapine/lutrol solid dispersions of improved stability and performances
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873680/
https://www.ncbi.nlm.nih.gov/pubmed/24300563
http://dx.doi.org/10.3390/pharmaceutics5040570
work_keys_str_mv AT cavallaricristina designofolanzapinelutrolsoliddispersionsofimprovedstabilityandperformances
AT finiadamo designofolanzapinelutrolsoliddispersionsofimprovedstabilityandperformances
AT ceschelgiancarlo designofolanzapinelutrolsoliddispersionsofimprovedstabilityandperformances